Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
Sacituzumab govitecan significantly improved progression-free survival and overall survival compared with physician's choice chemotherapy in heavily pretreated metastatic triple-negative breast cancer. This trial established sacituzumab govitecan as a standard later-line option for metastatic TNBC and was stopped early for compelling efficacy.
Key Result: PFS (BICR, patients without brain metastases) — 5.6 vs 1.7 months, HR 0.41 (95% CI 0.32–0.52; P<0.001)
Safety Signal: Neutropenia (grade 3: 34%, grade 4: 17%) required growth-factor support in 49% of patients; diarrhea grade 3 in 10%.
✅ Patient Eligibility
Must Have:
- Metastatic triple-negative breast cancer (ASCO-CAP criteria)
- ≥2 prior chemotherapy regimens for metastatic disease
- Prior taxane exposure (any setting)
- ECOG PS 0–1
Cannot Have:
- Active/symptomatic brain metastases (stable brain metastases permitted but excluded from primary endpoint)
- No upper limit on prior lines
💊 Dosing Quick Guide
Experimental Regimen
Sacituzumab govitecan: 10 mg/kg IV on days 1 and 8 Cycle: 21 days Duration: Until progression or unacceptable toxicity
Control Regimen
Physician's choice: Eribulin (54%), vinorelbine (20%), capecitabine (13%), or gemcitabine (12%)
No crossover permitted.
Key Dose Modifications [2]
- Dose reductions occurred in 22% of sacituzumab govitecan patients
- Monitor CBC before each dose; hold for ANC <1,500/mm³
- Manage diarrhea early with antidiarrheal agents
Mechanism: Sacituzumab govitecan is an anti-Trop-2 antibody-drug conjugate linked to SN-38 (topoisomerase I inhibitor) that delivers cytotoxic payload directly to Trop-2–expressing tumor cells [2].
⚠️ Safety Snapshot
| Grade ≥3 Toxicities | SG Grade 3 (n=258) | SG Grade 4 | Chemo Grade 3 (n=224) | Chemo Grade 4 |
|---|---|---|---|---|
| Neutropenia | 88 (34%) | 44 (17%) | 45 (20%) | 29 (13%) |
| Diarrhea | 27 (10%) | 0 | 1 (<1%) | 0 |
| Leukopenia | 23 (9%) | 3 (1%) | 10 (4%) | 2 (1%) |
| Anemia | 20 (8%) | 0 | 11 (5%) | 0 |
| Febrile neutropenia | 12 (5%) | 3 (1%) | 4 (2%) | 1 (<1%) |
⚠️ Neutropenia: Any grade 63%, Grade 3 34%, Grade 4 17%. Growth-factor support required in 49%.
Key safety metrics:
- Treatment-related deaths: 0 (SG) vs 1 (chemo — neutropenic sepsis)
- Discontinuations due to AE: 5% vs 5%
- Dose reductions: 22% vs 26%
- Serious AEs: 15% vs 8%
📊 Key Numbers
Median follow-up: 17.7 months
Primary efficacy population: patients without brain metastases (N=468)
| Outcome | Sacituzumab Govitecan | Chemotherapy | HR (95% CI) | p-value |
|---|---|---|---|---|
| PFS (BICR) — primary | 5.6 mo | 1.7 mo | 0.41 (0.32–0.52) | P<0.001 |
| OS | 12.1 mo | 6.7 mo | 0.48 (0.38–0.59) | P<0.001 |
| PFS (investigator) | 5.5 mo | 1.7 mo | 0.35 (0.28–0.44) | — |
| ORR | 35% | 5% | — | — |
| DOR (median) | 6.3 mo | 3.6 mo | 0.39 (0.14–1.07) | — |
Full population (N=529, including brain metastases):
| Outcome | Sacituzumab Govitecan | Chemotherapy | HR (95% CI) |
|---|---|---|---|
| PFS (BICR) | 4.8 mo | 1.7 mo | 0.43 (0.35–0.54) |
| OS | 11.8 mo | 6.9 mo | 0.51 (0.41–0.62) |
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| ASCENT | SG vs TPC | mTNBC, ≥2L | PFS (BICR) | 5.6 vs 1.7 mo; HR 0.41 | [1] |
| EMBRACE | Eribulin vs TPC | MBC (all subtypes), ≥2L | OS | 13.1 vs 10.6 mo; HR 0.81 | [4] |
| KEYNOTE-355 | Pembro + chemo vs chemo | mTNBC, 1L, CPS ≥10 | PFS | 9.7 vs 5.6 mo; HR 0.65 | [6] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
Age ≥65 yr: HR 0.22 (95% CI 0.12–0.40) — numerically greater benefit in older patients Prior PD-1/PD-L1 — Yes: HR 0.37 (95% CI 0.24–0.57) — benefit maintained after immunotherapy Liver metastases — Yes: HR 0.48 (95% CI 0.34–0.67) — effective despite poor-prognosis visceral disease Previous therapies >3: HR 0.48 (95% CI 0.32–0.72) — benefit preserved in heavily pretreated patients
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Approved (regular approval April 2021) for mTNBC ≥2 prior therapies [2] |
| EMA | Approved for mTNBC after ≥2 prior systemic therapies |
⚠️ Verify current regulatory status before prescribing.
NCCN: Preferred regimen, Category 1, for recurrent/metastatic TNBC [3]
⚡ Grey Zones
- Patients with active brain metastases were excluded from the primary analysis — efficacy in this population is uncertain
- Optimal sequencing relative to trastuzumab deruxtecan in HER2-low TNBC is undefined
- Whether earlier use (second-line) produces greater benefit than in this ≥third-line population is unknown
- No data on subsequent therapy outcomes after sacituzumab govitecan progression
- ~30% of patients had TNBC only at metastatic confirmation, not at initial diagnosis — biological implications uncertain
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541. doi:10.1056/NEJMoa2028485
- Trodelvy (sacituzumab govitecan-hziy) prescribing information. U.S. Food and Drug Administration. Revised 2023.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE). Lancet. 2011;377(9769):914-923.
- Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-2121.
- Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355). Lancet. 2020;396(10265):1817-1828.